Neurobehavioral Effects of Vigabatrin and Its Ability to Induce DNA Damage in Brain Cells After Acute Treatment in Rats

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2016 Sep 29

PMID 27678549

Citations 4

Authors

Karen Sousa

Natalia Decker

Thienne Rocha Pires

Debora Kuck Mausolff Papke

Vanessa Rodrigues Coelho

Pricila Pfluger

Patricia Pereira

Jaqueline Nascimento Picada

Affiliations

Soon will be listed here.

Abstract

Rationale: Vigabatrin (VGB) is a drug indicated mostly for the treatment of spasms in childhood and West's syndrome patients. This drug inhibits irreversibly the enzyme GABA-transaminase (GABA-T), increasing GABA concentrations and enhancing GABAergic neurotransmission in the brain, which is known to induce behavioral changes.

Objectives: The aims of this study were to evaluate the effects of VGB in the short-term memory (STM), long-term memory (LTM), motivation, locomotion, and exploratory behavior tests and to detect deleterious or protective effects on DNA in target tissues of the drug.

Methods: Male Wistar rats were treated with a single dose of VGB (100, 250, or 500 mg/kg) or saline solution before the inhibitory avoidance and open-field tasks. DNA damage was evaluated using the alkaline comet assay in peripheral blood, cerebral cortex, and hippocampus after behavioral testing.

Results: There was no significant difference in the inhibitory avoidance task between the treated groups and the saline group. In all tested doses, VGB reduced the number of rearings in the open-field task. Besides, VGB 500 mg/kg affected locomotion, though it was not able to induce any DNA damage.

Conclusions: VGB did not affect STM and LTM, but the drug impaired the exploration and locomotion likely associated with its sedative effect. In addition, no DNA damage in cortex and hippocampus was detected after behavioral testing, when brain GABA levels are already increased.

Citing Articles

Pharmacokinetics and tissue distribution of vigabatrin enantiomers in rats.

Zheng Q, He S, Xu S, Ma M, Fan M, Ge J Saudi Pharm J. 2024; 32(2):101934.

PMID: 38223203 PMC: 10787297. DOI: 10.1016/j.jsps.2023.101934.

The Discordance between Network Excitability and Cognitive Performance Following Vigabatrin Treatment during Epileptogenesis.

Lai M, Huang C Life (Basel). 2021; 11(11).

PMID: 34833089 PMC: 8618433. DOI: 10.3390/life11111213.

Antinociceptive and genotoxic assessments of the antagonist TRPV1 receptor SB-366791 on morphine-induced tolerance in mice.

Mazeto T, Picada J, Correa A, Rebelo I, Ribeiro M, Gomez M Naunyn Schmiedebergs Arch Pharmacol. 2019; 393(3):481-490.

PMID: 31655852 DOI: 10.1007/s00210-019-01748-6.

DNA damage and oxidative stress induced by seizures are decreased by anticonvulsant and neuroprotective effects of lobeline, a candidate to treat alcoholism.

da Costa E Silva L, Pereira P, Regner G, Boaretto F, Hoffmann C, Pfluger P Metab Brain Dis. 2017; 33(1):53-61.

PMID: 29032429 DOI: 10.1007/s11011-017-0130-1.

References

Czuczwar M, Kis J, Potasinski A, Turski W, Przesmycki K . Isobolographic analysis of interaction between vigabatrin and baclofen in the formalin test in mice. Pol J Pharmacol. 2002; 53(5):527-30. View

John R, Rimmer E, Williams J, Cole G, Fowler L, Richens A . Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin. Biochem Pharmacol. 1987; 36(9):1467-73. DOI: 10.1016/0006-2952(87)90112-2. View

Cavanna A, Ali F, Rickards H, McCorry D . Behavioral and cognitive effects of anti-epileptic drugs. Discov Med. 2010; 9(45):138-44. View

Makkar S, Zhang S, Cranney J . Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory. Neuropsychopharmacology. 2010; 35(8):1625-52. PMC: 3055480. DOI: 10.1038/npp.2010.53. View

Kaefer V, Semedo J, Kahl V, Von Borowsky R, Gianesini J, Ledur Kist T . DNA damage in brain cells and behavioral deficits in mice after treatment with high doses of amantadine. J Appl Toxicol. 2010; 30(8):745-53. DOI: 10.1002/jat.1550. View

Bolton J, Rimmer E, Williams J, Richens A . The effect of vigabatrin on brain and platelet GABA-transaminase activities. Br J Clin Pharmacol. 1989; 27 Suppl 1:35S-42S. PMC: 1379677. DOI: 10.1111/j.1365-2125.1989.tb03459.x. View

Kim J, McNally G, Richardson R . Recovery of fear memories in rats: role of gamma-amino butyric acid (GABA) in infantile amnesia. Behav Neurosci. 2006; 120(1):40-8. DOI: 10.1037/0735-7044.120.1.40. View

Pereira P, de Oliveira P, Ardenghi P, Rotta L, Henriques J, Picada J . Neuropharmacological analysis of caffeic acid in rats. Basic Clin Pharmacol Toxicol. 2006; 99(5):374-8. DOI: 10.1111/j.1742-7843.2006.pto_533.x. View

Hannila T, Sirvio J, Riekkinen P . The effect of gamma-vinyl-GABA on the performance of nucleus basalis-lesioned rats in spatial navigation task. Brain Res. 1990; 537(1-2):363-6. DOI: 10.1016/0006-8993(90)90387-q. View

10.

Nunez J, Alt J, McCarthy M . A novel model for prenatal brain damage. II. Long-term deficits in hippocampal cell number and hippocampal-dependent behavior following neonatal GABAA receptor activation. Exp Neurol. 2003; 181(2):270-80. DOI: 10.3201/eid0906.020377. View

11.

Picada J, Flores D, Zettler C, Marroni N, Roesler R, Henriques J . DNA damage in brain cells of mice treated with an oxidized form of apomorphine. Brain Res Mol Brain Res. 2003; 114(1):80-5. DOI: 10.1016/s0169-328x(03)00127-x. View

12.

Ghaffari H, Venkataramana M, Jalali Ghassam B, Nayaka S, Nataraju A, Geetha N . Rosmarinic acid mediated neuroprotective effects against H2O2-induced neuronal cell damage in N2A cells. Life Sci. 2014; 113(1-2):7-13. DOI: 10.1016/j.lfs.2014.07.010. View

13.

Bouwman B, van Lier H, Nitert H, Drinkenburg W, Coenen A, van Rijn C . The relationship between hippocampal EEG theta activity and locomotor behaviour in freely moving rats: effects of vigabatrin. Brain Res Bull. 2005; 64(6):505-9. DOI: 10.1016/j.brainresbull.2004.10.006. View

14.

Walzer M, Bekersky I, Wanaski S, Collins S, Jortner B, Patterson R . Oral toxicity of vigabatrin in immature rats: characterization of intramyelinic edema. Neurotoxicology. 2011; 32(6):963-74. DOI: 10.1016/j.neuro.2011.03.014. View

15.

Ebus S, IJff D, den Boer J, van Hall M, Klinkenberg S, van der Does A . Changes in the frequency of benign focal spikes accompany changes in central information processing speed: a prospective 2-year follow-up study. Epilepsy Behav. 2014; 43:8-15. DOI: 10.1016/j.yebeh.2014.11.027. View

16.

Shao L, Young L, Wang J . Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry. 2005; 58(11):879-84. DOI: 10.1016/j.biopsych.2005.04.052. View

17.

Pereira P, Tysca D, Oliveira P, Brum L, Picada J, Ardenghi P . Neurobehavioral and genotoxic aspects of rosmarinic acid. Pharmacol Res. 2005; 52(3):199-203. DOI: 10.1016/j.phrs.2005.03.003. View

18.

Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J . Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol. 1991; Suppl 2:S52-9. View

19.

Picada J, Schroder N, Izquierdo I, Henriques J, Roesler R . Differential neurobehavioral deficits induced by apomorphine and its oxidation product, 8-oxo-apomorphine-semiquinone, in rats. Eur J Pharmacol. 2002; 443(1-3):105-11. DOI: 10.1016/s0014-2999(02)01553-4. View

20.

Mazurkiewicz M, Sirvio J, Riekkinen Sr P . Effects of single and repeated administration of vigabatrin on the performance of non-epileptic rats in a delayed non-matching to position task. Epilepsy Res. 1993; 15(3):221-7. DOI: 10.1016/0920-1211(93)90059-g. View